Table E3.
Baseline clinical characteristics of groups treated vs not treated with TCZ
| Characteristic | TCZ |
||
|---|---|---|---|
| Treated (n = 58) | Not treated (n = 88) | P value | |
| Age (y) | 61 (54-70) | 64 (54-72) | .288 |
| Sex: male | 40 (69) | 57 (65) | .600 |
| Comorbidities (1 [0.68%]) | 35 (61) | 64 (73) | .124 |
| Hypertension (1 [0.68%]) | 17 (30) | 37 (42) | .124 |
| Obesity (1 [0.68%]) | 14 (25) | 9 (10) | .023 |
| Diabetes mellitus (1 [0.68%]) | 9 (16) | 16 (18) | .687 |
| COPD (1 [0.68%]) | 1 (2) | 8 (9) | .071 |
| Immune-mediated disease∗ (1 [0.68%]) | 5 (9) | 3 (3) | .181 |
| History of malignancy† (1 [0.68%]) | 7 (12) | 12 (14) | .763 |
| Others‡ (1 [0.68%]) | 30 (52) | 46 (52) | .892 |
| Duration of symptoms at admission (d) (1 [0.68%]) | 6 (5-7) | 7 (4-8) | .612 |
| Fever at admission (≥38ºC) (15 [10%]) | 17 (31) | 19 (25) | .483 |
| Baseline PaO2/FiO2 (5 [3%]) | 137 (88-232) | 248 (183-348) | <.001 |
| Treatment during hospitalization | |||
| Hydroxychloroquine (2 [1.35%]) | 53 (93) | 84 (98) | .171 |
| Lopinavir/Ritonavir (2 [1.35%]) | 51 (89) | 68 (79) | .103 |
| Azithromycin (2 [1.35%]) | 33 (58) | 49 (57) | .913 |
| IFN-β (2 [1.35%]) | 2 (4) | 5 (6) | .532 |
| Glucocorticoids (2 [1.35%]) | 38 (67) | 47 (55) | .152 |
| Methylprednisolone bolus (1 [0.68%]) | 31 (54) | 30 (35) | .018 |
| Laboratory findings | |||
| White blood cell count (103/mm3) (9 [6%]) | 7.99 (5.17-11.85) | 7.52 (5.4-10.36) | .527 |
| Lymphocyte count (103/mm3) (10 [6.76%]) | 0.74 (0.52-0.997) | 0.93 (0.66-1.47) | .001 |
| Creatinine (mg/dL) (7 [4.73%]) | 0.83 (0.70-1.05) | 0.90 (0.72-1.14) | .177 |
| Bilirubin (mg/dL) (9 [6.08%]) | 0.62 (0.46-1.04) | 0.52 (0.38-0.78) | .070 |
| AST (U/L) (9 [6.08%]) | 47 (29-77.50) | 34.5 (28-53) | .047 |
| ALT (U/L) (9 [6.08%]) | 37.5 (25-77) | 36 (22.5-64.5) | .588 |
| GGT (U/L) (26 [17.57%]) | 73 (41-186) | 71 (35-145) | .374 |
| LDH (U/L) (14 [9.46%]) | 425 (302-510) | 293.50 (221.50-388.50) | <.001 |
| CK (U/L) (102 [69%]) | 69 (38-270) | 75.5 (49-125) | .785 |
| Serum IL-6 (pg/mL) (7 [4.73%]) | 41.85 (12.37-71.95) | 16.25 (6.27-44.95) | .007 |
| Ferritin (ng/mL) (96 [64.86%]) | 1888 (1152-2844) | 1461 (471-1861) | .038 |
| CRP (mg/dL) (23 [15.54%]) | 13.73 (8.75-27.08) | 9.09 (4.78-19.31) | .005 |
| PCT (ng/mL) (52 [35.14%]) | 0.25 (0.13-0.36) | 0.14 (0.1-0.3) | .045 |
| D-dimer (mg/mL) (25 [16.89%]) | 0.75 (0.48-1.48) | 0.71 (0.53-1.22) | .491 |
| Radiologic findings (1 [0.68%]) | .818 | ||
| Clear | 4 (7) | 8 (8) | |
| Diffuse ground glass opacities | 18 (32) | 32 (37) | |
| Unilateral alveolar pattern | 10 (18) | 10 (11) | |
| Bilateral alveolar pattern | 25 (44) | 37 (43) | |
ALT, Alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase; GGT, gamma-glutamyl transferase; PCT, procalcitonin.
All categorical variables are expressed as number (%) and quantitative variables as median (p25-p75). Missing data are expressed as (number [%]). Variables not disclosing it do not present any missing values.
∗
Includes rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis, etc.
†
Includes solid organ and hematologic malignancies
‡
Includes obstructive sleep apnea syndrome, asthma, hypothyroidism, ischemic cardiomyopathy, etc.